ZA94155B - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
ZA94155B
ZA94155B ZA94155A ZA94155A ZA94155B ZA 94155 B ZA94155 B ZA 94155B ZA 94155 A ZA94155 A ZA 94155A ZA 94155 A ZA94155 A ZA 94155A ZA 94155 B ZA94155 B ZA 94155B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
ZA94155A
Other languages
English (en)
Inventor
Cecil Treadwell
Original Assignee
Adcock Ingram Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adcock Ingram Pharma filed Critical Adcock Ingram Pharma
Publication of ZA94155B publication Critical patent/ZA94155B/xx

Links

ZA94155A 1992-11-06 1994-01-11 Pharmaceutical composition ZA94155B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA928567 1992-11-06

Publications (1)

Publication Number Publication Date
ZA94155B true ZA94155B (en) 1995-07-11

Family

ID=25582297

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA94155A ZA94155B (en) 1992-11-06 1994-01-11 Pharmaceutical composition

Country Status (1)

Country Link
ZA (1) ZA94155B (xx)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035452A1 (en) * 1995-05-10 1996-11-14 Adcock Ingram Limited Pharmaceutical composition containing acetylcysteine, carbocysteine or erdosteine in combination with a beta 2 agonist and an expectorant for the treatment of respiratory tract disorders
WO1997003649A1 (en) * 1995-07-24 1997-02-06 Co-Ordinated Drug Development Ltd. Improvements in and relating to powders for use in dry powder inhalers
WO2005013963A1 (en) 2003-08-06 2005-02-17 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
US7011818B2 (en) 1995-01-31 2006-03-14 Vectura Limited Carrier particles for use in dry powder inhalers
WO2006030221A1 (en) * 2004-09-15 2006-03-23 Cipla Limited Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011818B2 (en) 1995-01-31 2006-03-14 Vectura Limited Carrier particles for use in dry powder inhalers
US7718163B2 (en) 1995-01-31 2010-05-18 Vectura Limited (01696917) Carrier particles for use in dry powder inhalers
US8920781B2 (en) 1995-01-31 2014-12-30 Vectura Limited Carrier particles for use in dry powder inhalers
WO1996035452A1 (en) * 1995-05-10 1996-11-14 Adcock Ingram Limited Pharmaceutical composition containing acetylcysteine, carbocysteine or erdosteine in combination with a beta 2 agonist and an expectorant for the treatment of respiratory tract disorders
WO1997003649A1 (en) * 1995-07-24 1997-02-06 Co-Ordinated Drug Development Ltd. Improvements in and relating to powders for use in dry powder inhalers
US6475523B1 (en) 1995-07-24 2002-11-05 Vectura Limited Powders comprising anti-adherant materials for use in dry powder inhalers
EP1213012A3 (en) * 1995-07-24 2002-12-04 Vectura Limited Improvements in and relating to powders for use in dry powder inhalers
WO2005013963A1 (en) 2003-08-06 2005-02-17 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
EP1658063B1 (en) * 2003-08-06 2014-03-12 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
WO2006030221A1 (en) * 2004-09-15 2006-03-23 Cipla Limited Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent

Similar Documents

Publication Publication Date Title
GB9224855D0 (en) Pharmaceutical compositions
GB9209078D0 (en) Pharmaceutical compositions
GB9319500D0 (en) Pharmaceutical composition
HUT66864A (en) Pharmaceutical compositions
GB2272375B (en) Pharmaceutical composition
EP0587047A3 (en) Gestagenes containing pharmaceutical composition
GB9209874D0 (en) Pharmaceutical compositions
CA2100836A1 (en) Pharmaceutical composition
ZA937592B (en) Pharmaceutical composition
ZA94155B (en) Pharmaceutical composition
ZA935078B (en) Pharmaceutical composition
GB9226377D0 (en) Pharmaceutical compositions
ZA935931B (en) Pharmaceutical composition
ZA924061B (en) Pharmaceutical composition
GB9211276D0 (en) Pharmaceutical compositions
ZA931984B (en) Pharmaceutical composition
GB9203248D0 (en) Pharmaceutical composition
GB9216596D0 (en) Pharmaceutical composition
GB9225170D0 (en) Pharmaceutical composition
GB9225159D0 (en) Pharmaceutical composition
GB9221003D0 (en) Pharmaceutical composition
ZA931863B (en) Pharmaceutical composition
GB9216600D0 (en) Pharmaceutical composition
GB9210335D0 (en) Pharmaceutical composition
GB9215976D0 (en) Pharmaceutical composition